AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$45.61 -1.88%

-$1.07 today

Market cap
$1.36B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.60M

Average 0.76M

ANAB EBITDA Margin

EBITDA as a percentage of revenue.

AnaptysBio, Inc.NASDAQ: ANAB

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -122.8%

EBITDA Margin was -122.8% in Q1 FY2026, down 48.5 pp from a year earlier. On a trailing-twelve-month basis it was 25.2%, up 93.4 pp year over year. Over 3 fiscal years it widened by 1052.7 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 144.4% for the fiscal year ending Dec 2026, up from 29.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-122.8%-187.4 pp QoQ
Last fiscal yearDec 2025
29.5%+131.1 pp YoY
LTMMar 2026
25.2%+93.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-48.5 pp+33.2 pp+81.7 pp
1 year+131.1 pp+114.8 pp-16.3 pp
3 years+1052.7 pp+78.7 pp-974.0 pp
5 years+63.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
29.5%
Year-over-year change
+131.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ANAB compares with its peers on the latest reported figures

  • ANAB's LTM Mar 2026 EBITDA Margin of 25.2% is the 2nd highest of the 7 companies compared; the peer median is -1197.4%.
  • Its year-over-year change of +93.4 pp is the 2nd highest of 5, against a peer median of -296.9 pp.
  • Over three fiscal years its change of +1052.7 pp compares with a peer median of -274.9 pp.
ANAB Competitors Peer median
EBITDA Margin for ANAB and competitors
Company Period LTM level YoY 3-year change
QTTBQ32 Bio Inc.LTM Mar 202641.2% —+616.4 pp
ANABAnaptysBio, Inc.LTM Mar 202625.2% +93.4 pp+1052.7 pp
XNCRXencor, Inc.LTM Jun 2026-117.7% -51.9 pp-9.6 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-843.9% -542.0 pp-540.2 pp
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-1550.9% +804.4 pp-7510.8 pp
IMVTImmunovant, Inc.LTM Sep 2026-7186.4% ——
CNTBConnect Biopharma Holdings LimitedFY2025-85279.7% -85223.0 pp—
MLTXMoonLake ImmunotherapeuticsFY2025— ——
ODTXOdyssey Therapeutics, Inc.—— ——
ANNXAnnexon, Inc.FY2025— ——
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
Peer median (excluding ANAB) -1197.4%-296.9 pp-274.9 pp

Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.18M10.29M17.16M91.28M234.6M
Cost of Revenue98.5M88.8M132.28M163.84M2.42M
Gross Profit(35.32M)(78.51M)(115.13M)(72.56M)232.18M
Gross Margin-55.9%-763.2%-671.0%-79.5%99.0%
Research & Development98.5M88.8M139.62M163.84M135.97M
Selling, General & Admin21.49M36.64M41.95M42.39M50.74M
Operating Expenses21.49M36.64M49.29M42.39M184.28M
Depreciation & Amortization2.09M2.34M652K2.4M2.42M
EBITDA(55.71M)(105.26M)(156.42M)(92.74M)69.25M
EBITDA Margin-88.2%-1023.2%-911.7%-101.6%29.5%
Operating Income(56.81M)(115.15M)(164.41M)(114.95M)47.9M
Operating Margin-89.9%-1119.4%-958.3%-125.9%20.4%
Interest Income431K7.55M18.87M19.79M13.5M
Interest Expense1.45M21.11M18.08M50.09M79.89M
Other Income / Expenses(982K)(13.55M)788K(30.28M)(60.96M)
Income Before Tax(57.8M)(128.7M)(163.62M)(145.23M)(13.07M)
Pre-Tax Margin-91.5%-1251.1%-953.7%-159.1%-5.6%
Income Tax Expense024K(4K)3K164K
Net Income(57.8M)(128.72M)(163.62M)(145.23M)(13.23M)
Net Margin-91.5%-1251.3%-953.7%-159.1%-5.6%
EPS (Basic)(2.11)(4.57)(6.08)(5.12)(0.46)
EPS (Diluted)(2.11)(4.57)(6.08)(5.12)(0.46)
Weighted Avg Shares27.43M28.17M26.92M28.38M27.79M
Weighted Avg Shares (Diluted)27.43M28.17M26.92M28.38M31.34M

AnaptysBio, Inc.

NASDAQ:ANAB

Intrinsic Alpha fair value

Locked

Current Price

$45.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.